Would these NZX50 listed Healthcare stocks -RYM, FPH, EBO Keep On Truckin’ in 2021?


  • Unlike other sectors that were adversely impacted by the pandemic, healthcare companies fared well in 2020.
  • Ryman Healthcare Limited witnessed witnessed a 12.8% rise in the reported (IFRS) profit taking it to $212.4m in its interim results.
  • Fisher & Paykel Healthcare Corporation noted 73% increase in the operating revenue for the period of 9 months ending December last year.


In the past year, several industries witnessed fluctuations, businesses came to a standstill, trade was disrupted due to COVID-19 and the several implications it brought about with it.

However, healthcare industry escaped unscathed from adverse repercussions of the coronavirus and witnessed growing demand in its products and services. As a consequence, several healthcare companies experienced increased profits during the period.

Source: © Scanrail | Megapixl.com

Let’s have a look at some leading NZX listed healthcare companies and see how they fared amidst the crisis.

Ryman Healthcare Limited (NZX:RYM)

One of the leading NZX listed healthcare companies, Ryman Healthcare performed fairly well despite the COVID-19 related restrictions. While there was a 14.2% drop to $88.4m in the unaudited underlying profits in half yearly report ended 30 September 2020. Further, the Company witnessed a 12.8% rise in the reported (IFRS) profit taking it to $212.4m. The Company also announced an interim dividend for its shareholders (standing at 8.8 cents per share) for the six-month period.

On 5 February, Ryman Healthcare last traded at $15.85, up by 0.44%.


Fisher & Paykel Healthcare Corporation (NZX:FPH)

Leading medical equipment producer, Fisher & Paykel witnessed a very strong trading despite COVID-19 in the year 2020.


It was revealed on 22 January that the Company saw a 73% increase in the operating revenue for the period of 9 months that ended on December 31, 2020. Also, during the same period, on the Hospital product group front, there was a 113% growth in operating revenue. In the same period, there was 54% increase in hospital consumables whereas the hospital hardware saw an increase of as much as 446% (in constant currency).


On 5 February, Fisher & Paykel Healthcare last traded at $33.50, down by 1.30%.


Also Read: Why Fisher & Paykel Healthcare stock is on a positive spree? | NZ |


Ebos Group Limited (NZX:EBO)

Healthcare and marketing distribution company, Ebos Group fared well in the year 2020, despite the many COVID-19 related challenges.


The same reflects in its annual report released in August for the period ended June 2020. There was a 26.5% revenue increase standing at $8.8billion. There was an 18% increase in the NPAT, to $162.5 million and 13.4% increase noted for underlying EBITDA standing at $296.6million.


On 5 February, Ebos Group last traded at $29.40, up by 0.62%.







We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK